NCT01361646

Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 129 (actual)
• Sponsor: LG Life Sciences · Industry
• Sex: Male
• Age: 20 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic / pharmacodynamic characteristics. Adverse events, physical examinations, vital signs, ECG and laboratory tests will be conducted for safety/tolerability evaluation and serial blood samples and urine collections for pharmacokinetic and pharmacodynamic evaluations will be conducted at specified time points.

Conditions

• Hyperuricemia
• Gout

Interventions

Type	Name	Description
DRUG	LC350189	Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg

Timeline

• Start date: 2011-06-01
• Primary completion: 2013-01-01
• Completion: 2013-01-01
• First posted: 2011-05-27
• Last updated: 2013-06-11

Locations

1 site across 1 country: South Korea